trifluoperazine has been researched along with Adenocarcinoma in 8 studies
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma." | 3.78 | Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. ( Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D, 2012) |
| " A significant potentiation of the P-30 protein-induced cell growth inhibition by tamoxifen as well as trifluoroperazine (Stelazine) in both the human A-549 lung carcinoma and the ASPC-1 pancreatic adenocarcinoma systems at wide ranges of drug concentrations was observed." | 3.68 | Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. ( Ardelt, W; Menduke, H; Mikulski, SM; Shogen, K; Viera, A, 1990) |
| " Noteworthy is that TFP in the dosage range used in SLDT experiments showed inhibitory effect on cell growth and DNA synthesis of MGC-803 cells documented in parallel experiments." | 1.28 | [Studies on the gap junctional intercellular communication (GJIC) of human stomach carcinoma cells in comparison with normal cells and the effect of the tumor promoter, TPA]. ( Han, YL; Lin, ZX; Trosko, JE; Zhang, RF; Zhau, YL, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Rizzuti, B | 1 |
| Lan, W | 1 |
| Santofimia-Castaño, P | 1 |
| Zhou, Z | 1 |
| Velázquez-Campoy, A | 1 |
| Abián, O | 1 |
| Peng, L | 1 |
| Neira, JL | 1 |
| Xia, Y | 1 |
| Iovanna, JL | 1 |
| Sangodkar, J | 1 |
| Dhawan, NS | 1 |
| Melville, H | 1 |
| Singh, VJ | 1 |
| Yuan, E | 1 |
| Rana, H | 1 |
| Izadmehr, S | 1 |
| Farrington, C | 1 |
| Mazhar, S | 1 |
| Katz, S | 1 |
| Albano, T | 1 |
| Arnovitz, P | 1 |
| Okrent, R | 1 |
| Ohlmeyer, M | 1 |
| Galsky, M | 1 |
| Burstein, D | 1 |
| Zhang, D | 1 |
| Politi, K | 1 |
| Difeo, A | 1 |
| Narla, G | 1 |
| Abad, A | 1 |
| Masuti, B | 1 |
| Camps, C | 1 |
| Font, A | 1 |
| Balañá, C | 1 |
| Vicent, JM | 1 |
| Sánchez, JJ | 1 |
| Xiong, W | 1 |
| Shen, H | 1 |
| Mikulski, SM | 1 |
| Viera, A | 1 |
| Ardelt, W | 1 |
| Menduke, H | 1 |
| Shogen, K | 1 |
| Lin, ZX | 1 |
| Zhau, YL | 1 |
| Han, YL | 1 |
| Zhang, RF | 1 |
| Trosko, JE | 1 |
| Soranzo, C | 1 |
| Ingrosso, A | 1 |
| Buffa, M | 1 |
| Della Torre, G | 1 |
| Gambetta, RA | 1 |
| Zunino, F | 1 |
| Hughes, TE | 1 |
| Ordovas, JM | 1 |
| Schaefer, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Apolipoprotein A-I Gene Polymorphism and Atherosclerosis[NCT00005183] | 0 participants | Observational | 1985-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for trifluoperazine and Adenocarcinoma
| Article | Year |
|---|---|
Design of Inhibitors of the Intrinsically Disordered Protein NUPR1: Balance between Drug Affinity and Target Function.
Topics: Adenocarcinoma; Animals; Basic Helix-Loop-Helix Transcription Factors; Calorimetry; Carcinoma, Pancr | 2021 |
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agen | 2012 |
Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Multiple; Epirubici | 1994 |
[Effect of calmodulin antagonist on chemosensitivity of primary cultured lung cancer cells].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Calmodu | 1995 |
Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Division; Drug Synergism; Humans; Lung Neoplasms; Pancre | 1990 |
[Studies on the gap junctional intercellular communication (GJIC) of human stomach carcinoma cells in comparison with normal cells and the effect of the tumor promoter, TPA].
Topics: Adenocarcinoma; Animals; Cell Communication; Cells, Cultured; Chick Embryo; Cricetinae; Humans; Inte | 1989 |
Changes in the three-dimensional organization of LoVo cells associated with resistance to doxorubicin.
Topics: Adenocarcinoma; Cell Aggregation; Cell Division; Colonic Neoplasms; Cyclosporins; Doxorubicin; Drug | 1989 |
Regulation of intestinal apolipoprotein B synthesis and secretion by Caco-2 cells. Lack of fatty acid effects and control by intracellular calcium ion.
Topics: Adenocarcinoma; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Calcimycin; Calcium; Calmo | 1988 |